Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial

Real-world data on venous thromboembolism (VTE) in Japanese patients with gynecological cancer are lacking. The GOTIC-VTE trial aimed to evaluate the frequency of VTE-associated events and risk factors at the time of cancer diagnosis and during 1-year follow-up. From July 2017 to February 2019, patients with endometrial, cervical, ovarian, tubal, or peritoneal cancer who underwent VTE screening within 2 months before registration, were enrolled. Of the 1008 patients enrolled, 881 were included in the analysis set, 51 (5.8%) had VTE at the time of cancer diagnosis (baseline), 7 (0.8%) had symptomatic VTE, and the majority had asymptomatic VTE (n = 44; 5.0%). Patients with ovarian, tubal, or peritoneal cancer had a higher incidence of VTE (13.7%) than those with other cancer types. During the 1-year follow-up, 0.9% (n = 8) of the patients had symptomatic VTE, 3.5% (n = 31) had composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.2% (n = 2) had bleeding events, and 4.3% (n = 38) had all-cause death, all of which were significantly higher in the VTE group at baseline. In the multivariate analysis, chemotherapy was an independent risk factor for composite VTE during the 1-year follow-up (hazard ratio 3.85, 95% confidence interval 1.39-13.63, p = 0.018). Among gynecological cancers, VTE incidence is particularly high in ovarian, tubal, or peritoneal cancer, and patients undergoing chemotherapy should be cautioned against VTE occurrence during treatment.The GOTIC-VTE trial Unique identifier, jRCTs031180124; Registration date, April 06, 2017.

Authors

Institutions

Publication Details

Journal
Journal of Thrombosis and Thrombolysis
Published
2024-11-27
DOI
https://doi.org/10.1007/s11239-024-03055-1
Citations
1
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial

Toshiaki Yasuoka, M. Suzuki, Masashi Takano, Akira Mitsuhashi et al.
1 citations
Journal of Thrombosis and Thrombolysis
Venous Thromboembolism Diagnosis and Management
0.55
article

Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial

Toshiaki Yasuoka, M. Suzuki, Masashi Takano, Akira Mitsuhashi, Keiichi Fujiwara, Morikazu Miyamoto, Yoshinobu Hamada, Tomonori Nagai, Michitaka Ohwada, Takashi Hirakawa, Yoshifumi Takahashi, Shoji Nagao, Masaya Uno, Mayuyo Mori‐Uchino, Kosei Hasegawa, Toyomi Satoh, Maiko Miwa, Kouji Yamamoto, Hiroyuki Fujiwara, Soichi Yamashita, Satoshi Yamaguchi
article en
1 citations

Abstract

Real-world data on venous thromboembolism (VTE) in Japanese patients with gynecological cancer are lacking. The GOTIC-VTE trial aimed to evaluate the frequency of VTE-associated events and risk factors at the time of cancer diagnosis and during 1-year follow-up. From July 2017 to February 2019, patients with endometrial, cervical, ovarian, tubal, or peritoneal cancer who underwent VTE screening within 2 months before registration, were enrolled. Of the 1008 patients enrolled, 881 were included in the analysis set, 51 (5.8%) had VTE at the time of cancer diagnosis (baseline), 7 (0.8%) had symptomatic VTE, and the majority had asymptomatic VTE (n = 44; 5.0%). Patients with ovarian, tubal, or peritoneal cancer had a higher incidence of VTE (13.7%) than those with other cancer types. During the 1-year follow-up, 0.9% (n = 8) of the patients had symptomatic VTE, 3.5% (n = 31) had composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.2% (n = 2) had bleeding events, and 4.3% (n = 38) had all-cause death, all of which were significantly higher in the VTE group at baseline. In the multivariate analysis, chemotherapy was an independent risk factor for composite VTE during the 1-year follow-up (hazard ratio 3.85, 95% confidence interval 1.39-13.63, p = 0.018). Among gynecological cancers, VTE incidence is particularly high in ovarian, tubal, or peritoneal cancer, and patients undergoing chemotherapy should be cautioned against VTE occurrence during treatment.The GOTIC-VTE trial Unique identifier, jRCTs031180124; Registration date, April 06, 2017.

Journal of Thrombosis and ThrombolysisVol. 58(2)
University of Tsukuba (JP), Jichi Medical University (JP), Okayama University (JP), Gunma University (JP), Gunma Prefectural Cardiovascular Center (JP), Tokyo National Hospital (JP), Social Insurance Saitama Chuo Hospital (JP), Hyogo Prefectural Cancer Center (JP), Ehime University (JP), National Defense Medical College (JP), The University of Tokyo (JP), Dokkyo Medical University (JP), International University of Health and Welfare (JP), Saitama Medical University (JP), Yokohama City University (JP)
Daiichi-Sankyo
Good health and well-being
Openalex Percentile: Top 29%
Venous Thromboembolism Diagnosis and Management
0.55
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.